[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100586487":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":10,"locations":10,"responsibleParty":23,"collaborators":10,"id":25,"slug":10,"hasResults":26,"nctId":27,"briefTitle":28,"officialTitle":29,"acronym":10,"eligibilityCriteria":30,"healthyVolunteers":26,"sex":31,"minAge":32,"maxAge":10,"enrollmentInfo":33,"targetDuration":10,"studyType":36,"phases":10,"briefSummary":37,"conditions":38,"keywords":41,"overallStatus":43,"whyStopped":10,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":10},{"fullName":5,"class":6},"Ain Shams University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Prostatic adenocarcinoma",null,"Localized intermediate-risk prostatic adenocarcinoma",[13],"Procedure: Focal laser ablation",[15,20],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"PROCEDURE","Focal laser ablation","Targeted focal laser ablation",[9],{"type":16,"name":17,"description":21,"armGroupLabels":22,"otherNames":10},"Targeted focal laser ablation of localized intermediate-risk prostate cancer",[9],{"type":24,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100586487",false,"NCT06916013","Focal Laser Ablation in Prostate Cancer","Transperineal Targeted Focal Laser Ablation of Localized Intermediate Risk Prostatic Adenocarcinoma (Pilot Study)","Inclusion Criteria:\n\n* Prostate cancer visible on mpMRI or PSMA PET\u002FCT and positive in the targeted biopsy.\n* Gleason score 7 (ISUP grade 2\u002F3)\n* PSA 10-20 ng\u002FmL\n* Clinical stage T2b\n* Refusing radical prostatectomy.\n\nExclusion Criteria:\n\n* Prostate cancer invisible on mpMRI or PSMA PET\u002FCT but positive in the systematic biopsies.\n* Presence of \\>2 MRI-visible lesions and positive in the biopsies.\n* Extracapsular extension\n* Seminal vesicle invasion\n* Presence of metastases detected by imaging\n* Gleason Score \\> 7\n* Stage \\> T2b\n* PSA \\> 20 ng\u002FmL\n* Urinary tract infection (UTI)\n* Severe lower urinary tract symptoms defined as an IPSS \\>20\n* Severe coagulation disorders\n* Inadequate compliance\n* Contraindications to MRI\n* Paramagnetic contrast agent allergy\n* Acute and\u002For chronic renal failure","MALE","45 Years",{"count":34,"type":35},30,"ESTIMATED","OBSERVATIONAL","To assess the effectiveness of MRI-US or PSMA PET\u002FCT-U\u002FS fusion-guided focal laser ablation (FLA) for the treatment of a localized, intermediate-risk prostate cancer in terms of short-term oncological \\& functional outcomes.",[39,40],"Prostate Cancer","Laser",[42,40],"Prostate cancer","NOT_YET_RECRUITING","2025-04-04",{"date":46,"type":47},"2025-04-08","ACTUAL",{"date":49,"type":35},"2025-04-20",{"date":51,"type":35},"2027-08-20",{"name":5,"class":6}]